SEC Filing Summary: India Globalization Capital, Inc. (IGC Pharma, Inc.)
Business Context and Reporting Period
This Form 8-K was filed on February 6, 2012, reporting events occurring on February 2, 2012. The registrant, India Globalization Capital, Inc. (also referenced as IGC Pharma, Inc. in the request metadata), is incorporated in Maryland. The filing primarily addresses the completion of a corporate acquisition.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification of a corporate event rather than a financial statement.
Material Changes
- Acquisition Completion: The Company announced the completion of its acquisition of "Ironman."
- Strategic Benefits: The filing references a press release (Exhibit 99.1) detailing the related benefits of this acquisition, though specific operational or financial impacts are not enumerated in the text of the 8-K itself.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the general context of the acquisition. The document incorporates a press release by reference for further details on the transaction's benefits.
Investor Verification Checklist
- Verify the specific terms and consideration paid for the acquisition of "Ironman" by reviewing the attached Press Release (Exhibit 99.1).
- Confirm the exact nature of the "related benefits" cited in the press release to assess the strategic value of the transaction.
- Check subsequent filings (e.g., 10-K or 10-Q) for the financial impact of the Ironman acquisition on the Company's consolidated results.
- Clarify the relationship between the registrant name "India Globalization Capital, Inc." and the ticker/name "IGC Pharma, Inc." to ensure accurate entity tracking.